Related Experiment Video
Updated: Jun 7, 2026

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
Published on: January 7, 2022
Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan
Jennifer Campbell1, Atul K Singh, John P Santa Maria
1Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115, United States.
Abstract:
Methicillin resistance in Staphylococcus aureus depends on the production of mecA, which encodes penicillin-binding protein 2A (PBP2A), an acquired peptidoglycan transpeptidase (TP) with reduced susceptibility to β-lactam antibiotics. PBP2A cross-links nascent peptidoglycan when the native TPs are inhibited by β-lactams. Although mecA expression is essential for β-lactam resistance, it is not sufficient. Here we show that blocking the expression of wall teichoic acids (WTAs) by inhibiting the first enzyme in the pathway, TarO, sensitizes methicillin-resistant S. aureus (MRSA) strains to β-lactams even though the β-lactam-resistant transpeptidase, PBP2A, is still expressed. The dramatic synergy between TarO inhibitors and β-lactams is noteworthy not simply because strategies to overcome MRSA are desperately needed but because neither TarO nor the activities of the native TPs are essential in MRSA strains. The "synthetic lethality" of inhibiting TarO and the native TPs suggests a functional connection between ongoing WTA expression and peptidoglycan assembly in S. aureus. Indeed, transmission electron microscopy shows that S. aureus cells blocked in WTA synthesis have extensive defects in septation and cell separation, indicating dysregulated cell wall assembly and degradation. Our studies imply that WTAs play a fundamental role in S. aureus cell division and raise the possibility that synthetic lethal compound combinations may have therapeutic utility for overcoming antibiotic-resistant bacterial infections.
Insights
Blocking wall teichoic acid (WTA) synthesis in methicillin-resistant Staphylococcus aureus (MRSA) with TarO inhibitors resensitizes MRSA to beta-lactams. This synthetic lethality offers a novel strategy against antibiotic-resistant infections.
Area of Science:
- Microbiology
- Molecular Biology
- Drug Discovery
Background:
- Methicillin resistance in Staphylococcus aureus (MRSA) is primarily mediated by the mecA gene, encoding penicillin-binding protein 2A (PBP2A).
- While PBP2A confers resistance to beta-lactam antibiotics, its expression alone is insufficient for full resistance.
- Effective strategies to combat MRSA are urgently needed due to rising antibiotic resistance.
Purpose of the Study:
- To investigate the role of wall teichoic acids (WTAs) in MRSA beta-lactam resistance.
- To explore the potential of inhibiting WTA synthesis as a therapeutic approach against MRSA.
- To identify synergistic drug combinations for overcoming antibiotic resistance.
Main Methods:
- Inhibition of TarO, the first enzyme in the WTA synthesis pathway.
- Treatment of MRSA strains with TarO inhibitors alone and in combination with beta-lactam antibiotics.
- Assessment of beta-lactam susceptibility.
- Transmission electron microscopy to analyze cell wall structure and division.
Main Results:
- Inhibiting TarO sensitized MRSA strains to beta-lactams, even with PBP2A expression.
- A synergistic effect was observed between TarO inhibitors and beta-lactams.
- Blocking WTA synthesis led to significant defects in S. aureus cell septation and separation.
- These findings suggest a functional link between WTA synthesis and peptidoglycan assembly.
Conclusions:
- Wall teichoic acids play a critical role in Staphylococcus aureus cell division.
- The combination of TarO inhibitors and beta-lactams demonstrates synthetic lethality against MRSA.
- This approach holds therapeutic potential for treating antibiotic-resistant bacterial infections.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Peptidoglycan Synthesis
Bacterial Cell Wall
Archaeal Cell Wall
Mechanism of Antibiotic Resistance in MRSA
Bacterial Toxins
